Caribou Biosciences (CRBU) Interest Expenses (2020 - 2021)
Caribou Biosciences (CRBU) reported Interest Expenses of $2000.0 for Q2 2021, down 60.0% year-over-year from $5000.0 in Q2 2020, and down 66.67% quarter-over-quarter from $6000.0 in Q4 2020.
Caribou Biosciences (CRBU) Interest Expenses (2020 - 2021) Analysis & Trends
Caribou Biosciences (CRBU) has 2 years of Interest Expenses data on file, last reported at $2000.0 in Q2 2021.
- Interest Expenses for Q2 2021 came in at $2000.0, down 60.0% year-over-year; the trailing twelve-month figure through Mar 2022 was $2000.0 (down 88.24% YoY), and the FY2021 annual result was $8000.0, down 60.0% from the prior year.
- Interest Expenses slipped to $2000.0 in Q2 2021 per CRBU's latest filing, from $6000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $6000.0 in Q3 2020 and troughed at $2000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2020 | 6,000.00 |
| Sep 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 5,000.00 |
| Jun 30, 2020 | 5,000.00 |